ISCR's Davis On Pandemic Adaptations, Value Of Multi-Regional Trials
Varying Implementation Of India's Trial Waiver Clause
Executive Summary
The new chief of the Indian Society for Clinical Research, Sanish Davis, tells Scrip how the Indian trials segment coped amid pandemic upheaval, emphasizing the need for stakeholder “sensitization and socialization” of the concepts of virtual/hybrid trials as part of efforts to mainstream these. The executive also shared his views on India’s trial waiver clause.
You may also be interested in...
MSD Licenses Molnupiravir In India
MSD India outlines further specifics around the just-announced voluntary licensing deal for molnupiravir with Indian firms, noting an expectation to discuss local data needs with the country’s regulator. All eyes are also on whether non-licensee Natco will stay the course for its application for the investigational antiviral.
Molnupiravir India Licenses: Nuances, Local Data In Focus
MSD-India Region chief outlines further specifics around the just-announced voluntary licensing deal for molnupiravir with Indian firms, noting an expectation to discuss local data needs with the country’s regulator. All eyes are also on whether non-licensee Natco will stay the course for its application for the investigational antiviral.
Pandemic Perspectives: The Lost Trials Of 2020
New development programs fell sharply in the early part of the year as COVID-19 spread around the world, but activity picked up in the second half. Oncology trials rebounded strongly and infectious disease trials ballooned, but autoimmune and CNS studies took a hit.